
U.S.-Based Magrathea Launches Next-Gen Magnesium Production Technology, Advances Plans to Scale
'Magnesium is one of the most important critical materials, but NATO countries face a dire shortage of non-China supply,' Alex Grant, CEO of Magrathea, said. 'Western nations must view this supply crisis as a national security emergency.'
'At our core, Magrathea's innovative technology revitalizes a proven process with our own twist for considerable efficiency improvement and expense reduction,' Mr. Grant continued. 'We expect to reduce the technology's operating expenses to make it cost-competitive with alternative production methods that exist today, including in China. Magrathea is in conversations with several major defense, chemical and mining industrial players to form a strategic partnership to scale up our technology as the first new commercial-scale magnesium electrolyzer in the United States in the past 50 years.'
Over the coming months, Magrathea will use data gathered from the pilot-scale electrolyzer to create a scalable technical model aimed at achieving the highest efficiencies from both environmental and economic perspectives. The Company will focus on obtaining process data, minimizing total electricity use, recycling energy in strategic ways and optimizing the dehydration process, which offers the biggest opportunity for cost reduction in the electrolytic magnesium metal production process. These technical efforts are expected to significantly reduce the carbon footprint and operating expenditure of future commercial plants. The data and key processing learnings are also expected to help streamline permitting processes for future facilities given the inherent environmental benefits of the technology.
Magrathea and Magnesium Highlights
The 'Gateway Metal': Magnesium unlocks a wide range of applications, such as stiffening aluminum in alloys, steel making, nuclear inputs, automotive, aerospace, and next-generation defense applications.
Solving a National Security Emergency: Russia and China currently control 90% of the global primary magnesium supply with no significant producer in any NATO country.
First Mover Advantage: Magrathea is the most advanced new producer of magnesium metal with significant intellectual property including patents and trade secrets.
Existing Operations: Magrathea's operational pilot plant in California can produce 4,000 pounds of magnesium annually at full capacity.
Low Operational Expense: Magrathea's technology demonstrates competitive operating costs, leveraging abundantly available seawater and renewable energy as feedstock.
Carbon Neutral: Technology produces 0 kg CO2 eq./kg magnesium compared to over 40 kg CO2 eq./kg magnesium with the incumbent Chinese process, which is expected to further streamline permitting processes for future scaled facilities.
Scalable to Meet Demand: Magrathea – in partnership with a strategic partner – plans to deploy its technology at a scaled facility by 2027 to produce up to 2 million pounds of magnesium per year, enough to support the equivalent production of thousands of Black Hawk helicopters annually.
Significant Commercial Traction: Magrathea has signed agreements with more than 25 companies, including 10 connected to the U.S. defense industry, an offtake agreement with a global automaker, and a resource supply agreement with Cargill.
Additional Market Opportunities: In addition to magnesium, Magrathea produces chloride co-products, which have a wide range of end-markets such as bleach, to unlock more value and improve project economics.
Strong Engineering Partnership: Magrathea is collaborating with Sedgman Novopro, an engineering firm specialized in mining and mineral processing, to support its scale-up engineering and design program.
Backed By Marquee Investors: Technology is backed by credible investors, including the U.S. Department of Defense, Capricorn, VoLo Earth, Exor Ventures, Sam Altman, and leaders at Glencore, Mitra Chem, Tesla, and many more.
About Magrathea
Magrathea is a technology company based in California that has developed a process for making magnesium metal from seawater and brines to help the West solve its magnesium shortage. Magnesium is essential for a wide range of applications such as stiffening aluminum in alloys, steel making, inputs for nuclear applications, automotive, aerospace, and next-generation defense applications. The company's technology is expected to be the largest primary production solution across NATO countries by 2030. For more information, please visit https://www.magratheametals.com/.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


San Francisco Chronicle
a few seconds ago
- San Francisco Chronicle
Company advised by Trump sons said it hoped to benefit from fed money, then took it back
NEW YORK (AP) — A public document filed by a company that just hired President Donald Trump's two oldest sons as advisers included a sentence early Monday that said it hoped to benefit from grants and other incentives from the federal government, which their father happens to lead. But when The Associated Press asked the Trump family business about the apparent conflict of interest, the document was revised and the line taken out. Eric Trump and Donald Trump Jr. are getting 'founder shares' worth millions of dollars in New America Acquisition 1 Corp., a company with no operating business that hopes to fill that hole by purchasing an American company that can play 'a meaningful role in revitalizing domestic manufacturing,' according to to the filing. The president has geared his trade policy toward boosting manufacturing in the U.S. The original version of the securities filing said the target company should be 'well positioned' to tap federal or state government incentives. That reference was taken out of the revised version of the filing. The Trump Organization didn't reply to a question about whether New America still planned to benefit from government programs or why the line was cut. But the outside law firm Paul Hastings that helped prepare the document sent an email to AP saying it was 'mistake' made by 'scriveners,' an old term for transcribers of legal papers. Kathleen Clark, an expert in government ethics, said any excuses are too late because the Trumps had already tipped their hand. 'They just deleted the language. They haven't committed not to do what they said earlier today they were planning to do," said the Washington University law professor and Trump critic. "It's an attempt to exploit public office for private profit.' New America is what's know as a special purpose acquisition company, or SPAC. It's a publicly traded company that exists solely to use its funds to acquire another company and take the target public. New America plans to raise money by selling stock on the New York Stock Exchange at $10 a share. That will hand the two Trump sons a total of $5 million in paper wealth on the first day of trading. The company hopes to sell enough shares to raise $300 million, which it then plans to use buying a yet unidentified manufacturer. A press release issued by New America saying it was focused on 'American values and priorities." It made no mention of the aim to get government incentives. The filing to New America's potential new investors to the Securities and Exchange Commission was explicit about what it was looking for in a target company. It said, among other things, it wanted a company that can ride 'public policy tailwinds" by benefiting from federal or state 'grants, tax credits, government contracts or preferential procurement programs.'


NBC News
31 minutes ago
- NBC News
U.S. Army trains with drones as new tech transforms battlefields overseas
The U.S. Army is training with and integrating small drones into combat. NBC News' Courtney Kube reports from Poland where American troops are learning about tracking and jamming enemy drones to transform the battlefield. Aug. 4, 2025
Yahoo
an hour ago
- Yahoo
Why Curaleaf Stock Popped by 15% on Monday
Key Points Good news benefiting the cannabis industry was beneficial for the company too. There were pot-positive developments on both the medical and political fronts. 10 stocks we like better than Curaleaf › Pardon the use of the adjective, but it was obvious on Monday that the market has high hopes for cannabis company Curaleaf (OTC: CURLF). Investors piled into the stock after some positive news developments affecting its industry hit the headlines. By the time the smoke had cleared, Curaleaf was left standing with a more than 15% gain in its stock price that day. This obliterated the 1.4% advance of the S&P 500 index. Drug of choice The first news item producing that buzz was research published by the influential American Medical Association (AMA). In its Journal of the American Medical Association, the AMA detailed research from a survey that evaluated a clutch of drugs for how they affected eating disorders. Of the numerous drugs tested, the Journal noted, cannabis and psychedelic compounds were the highest-rated for alleviating symptoms of eating disorders. On top of that, marijuana and the psychedelics LSD and psilocybin also performed well in terms of overall mental health. These contrasted with the generally weak showing of nicotine and alcohol, which the Journal said were frequently ranked by the respondents as being the most harmful substances. Marijuana is legally sold as a medicine to qualifying patients in most U.S. states. If the drug can indeed treat eating disorders, this could dramatically enhance its appeal as a medical drug. Pot lobbying Another item of interest was Federal Election Commission (FEC) filings cited by several media outlets revealing that a pot industry-supported political action committee (PAC) made a meaty donation to President Trump's MAGA Inc. This is a so-called "super PAC" entitled to raise unlimited amounts of money to support political figures. The American Rights and Reform PAC, fueled by donations from marijuana companies, has donated $1 million to MAGA Inc. Although that's relatively small given the over $177 million the latter absorbed in the first six months of the year, this does indicate that the weed industry is actively lobbying influential people in U.S. politics. Should you buy stock in Curaleaf right now? Before you buy stock in Curaleaf, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Curaleaf wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Curaleaf Stock Popped by 15% on Monday was originally published by The Motley Fool Sign in to access your portfolio